Cargando…

Radiological and Clinical Efficacy of Intra-Arterial (90)Y-DOTATATE in Patients with Unresectable, Progressive, Liver Dominant Neuroendocrine Neoplasms

This study was performed to determine if intra-arterial (i.a.) administration of (90)Y DOTATATE can provide an effective and safe alternative to the accepted standard for i.v. of peptide receptor radionuclide therapy (PRRT) in liver-dominant metastases of gastrointestinal pancreatic neuroendocrine n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolasińska-Ćwikła, Agnieszka, Nowicki, Mirosław L., Sankowski, Artur J., Pałucki, Jakub M., Buscombe, John R., Glinka, Lidia, Ćwikła, Jarosław B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074370/ https://www.ncbi.nlm.nih.gov/pubmed/33924160 http://dx.doi.org/10.3390/jcm10081794

Ejemplares similares

Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I–IV Stage
por: Lowczak, Anna, et al.
Publicado: (2021)

Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
por: Lowczak, Anna, et al.
Publicado: (2020)

Initial Study of Radiological and Clinical Efficacy Radioembolization Using (188)Re-Human Serum Albumin (HSA) Microspheres in Patients with Progressive, Unresectable Primary or Secondary Liver Cancers
por: Nowicki, Mirosław L., et al.
Publicado: (2014)

Disseminated Pancreatic Neuroendocrine Neoplasm (NEN) with an Uncommon Localisation in the Central Nervous System. A Case Report
por: Białkowska, Joanna, et al.
Publicado: (2017)

A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation
por: Kolasinska-Ćwikła, Agnieszka, et al.
Publicado: (2019)

The clinical value of MRI using single-shot echoplanar DWI to identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement
por: Sankowski, Artur J., et al.
Publicado: (2012)

Analysis of Patients with NET G1/G2 Neuroendocrine Tumors of the Small Intestine in the Course of Carcinoid Heart Disease—A Retrospective Study
por: Konsek-Komorowska, Sonia J., et al.
Publicado: (2023)

Severe ectopic Cushing syndrome in a transgender man with a metastatic gastrinoma and an adrenal tumor—A case report and review of the literature
por: Wydra, Arnika, et al.
Publicado: (2023)

Adrenal incidentaloma imaging – the first steps in therapeutic management
por: Papierska, Lucyna, et al.
Publicado: (2013)

Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine
por: Fuksiewicz, Małgorzata, et al.
Publicado: (2018)

The comparison of efficacy of different imaging techniques (conventional radiography, ultrasonography, magnetic resonance) in assessment of wrist joints and metacarpophalangeal joints in patients with psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with (177)Lu DOTATATE (LuTate)
por: Alipour, R., et al.
Publicado: (2023)

Radiosynovectomy in rheumatic diseases
por: Ćwikła, Jarosław B., et al.
Publicado: (2014)

Serum levels of neuron-specific enolase as a prognostic factor for disease progression in patients with GET/NEN in the pancreas and the small intestine
por: Fuksiewicz, Malgorzata, et al.
Publicado: (2022)

Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?
por: Kunikowska, Jolanta, et al.
Publicado: (2011)

Initial clinical evaluation of indigenous (90)Y-DOTATATE in sequential duo-PRRT approach ((177)Lu-DOTATATE and (90)Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, (90)Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects
por: Parghane, Rahul V., et al.
Publicado: (2020)

The HSP90 inhibitor onalespib potentiates (177)Lu-DOTATATE therapy in neuroendocrine tumor cells
por: Lundsten, Sara, et al.
Publicado: (2019)

Immunohistochemical Subtypes of The Breast Cancer in The Ultrasound and Clinical Aspect – Literature Review
por: Dobruch-Sobczak, Katarzyna, et al.
Publicado: (2022)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
por: Kos-Kudła, Beata, et al.
Publicado: (2017)

Initial Experience with (64)Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET
por: Loft, Mathias, et al.
Publicado: (2021)

Current imaging techniques in rheumatology: MRI, scintigraphy and PET
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2013)

The Diagnostic and Grading Accuracy of (68)Ga-DOTATATE and (18)F-FDG PET/MR for Pancreatic Neuroendocrine Neoplasms
por: Zhou, Jinxin, et al.
Publicado: (2022)

Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
por: Mitjavila, Mercedes, et al.
Publicado: (2023)

Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
por: Smith-Palmer, J., et al.
Publicado: (2021)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

THU508 Does Mid-treatment Response To 177Lu-DOTATATE Predict Treatment Outcome In Patients With Neuroendocrine Neoplasms?
por: Halperin, Reut, et al.
Publicado: (2023)

(90)Y/(177)Lu-DOTATATE therapy: survival of the fittest?
por: Brans, Boudewijn, et al.
Publicado: (2011)

Clinical and Prognostic Value of PET/CT Imaging with Combination of (68)Ga-DOTATATE and (18)F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Zhang, Panpan, et al.
Publicado: (2018)

Evaluation of (18)F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with (68)Ga-DOTATATE PET/CT
por: Hou, Jiale, et al.
Publicado: (2021)

A convolutional neural network for total tumor segmentation in [(64)Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms
por: Carlsen, Esben Andreas, et al.
Publicado: (2022)

Induction therapy with (177)Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients
por: Minczeles, Noémie S., et al.
Publicado: (2022)

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
por: Vida Navas, Elena María, et al.
Publicado: (2021)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020)

N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy ((1)H MRS) in patients with mild cognitive impairment (MCI)
por: Walecki, Jerzy, et al.
Publicado: (2011)

The use of radiosynovectomy in patients with juvenile idiopathic arthritis. Assessment of treatment efficacy and safety
por: Gazda, Agnieszka, et al.
Publicado: (2021)

Condition-Based Failure-Free Time Estimation of a Pump
por: Ćwikła, Grzegorz, et al.
Publicado: (2023)

Tandem peptide receptor radionuclide therapy using (90)Y/(177)Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

Recurrent hypoglycaemia in a type 2 diabetes patient – diagnostic difficulties
por: Grycewicz, Joanna, et al.
Publicado: (2010)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3dk4hg8g7mpqrt5jcsbuhr90kf